Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
53.29
+0.33 (0.62%)
Jun 22, 2026, 10:45 AM EDT - Market open
Royalty Pharma Revenue
Royalty Pharma had revenue of $630.58M in the quarter ending March 31, 2026, with 10.97% growth. This brings the company's revenue in the last twelve months to $2.44B, up 7.80% year-over-year. In the year 2025, Royalty Pharma had annual revenue of $2.38B with 5.06% growth.
Revenue (ttm)
$2.44B
Revenue Growth
+7.80%
P/S Ratio
12.50
Revenue / Employee
$24,405,220
Employees
100
Market Cap
30.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.38B | 114.61M | 5.06% |
| Dec 31, 2024 | 2.26B | -90.97M | -3.86% |
| Dec 31, 2023 | 2.35B | 117.33M | 5.24% |
| Dec 31, 2022 | 2.24B | -52.24M | -2.28% |
| Dec 31, 2021 | 2.29B | 167.11M | 7.87% |
| Dec 31, 2020 | 2.12B | 308.10M | 16.98% |
| Dec 31, 2019 | 1.81B | 19.36M | 1.08% |
| Dec 31, 2018 | 1.79B | 196.96M | 12.33% |
| Dec 31, 2017 | 1.60B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 14.92B |
| BeOne Medicines AG | 5.70B |
| Incyte | 5.36B |
| argenx SE | 4.74B |
| Alnylam Pharmaceuticals | 4.29B |
| Genmab | 3.90B |
| BioNTech SE | 3.23B |
| Moderna | 2.23B |
RPRX News
- 11 days ago - Healthcare ETFs: From Broad Exposure to Big Breakthroughs - ETF Trends
- 12 days ago - Royalty Pharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 17 days ago - Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Royalty Pharma Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 5 weeks ago - Royalty Pharma Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - Royalty Pharma Slides: Corporate presentation - Filings
- 6 weeks ago - Royalty Pharma to present at upcoming investor conferences - GlobeNewsWire
- 6 weeks ago - Royalty Pharma price target raised to $64 from $63 at Morgan Stanley - TheFly